No, Symbicort should NOT be used as a rescue inhaler in patients already on Trelegy
Symbicort is explicitly contraindicated as a rescue medication when used outside of specific MART (Maintenance And Reliever Therapy) protocols, and MART is only approved for asthma—not for COPD patients on triple therapy like Trelegy.
Why This Is Not Appropriate
FDA Labeling Is Clear
The Symbicort FDA label explicitly states that "SYMBICORT is not used to relieve sudden breathing problems and will not replace a rescue inhaler" 1. The label further instructs patients to "seek medical attention immediately if they experience decreasing effectiveness of inhaled, short-acting beta2-agonists" 1. This unambiguously positions Symbicort as maintenance therapy, not rescue therapy in standard use.
The MART Exception Applies Only to Asthma
Symbicort can be used as both maintenance and reliever therapy (MART/SMART regimen) but only in asthma patients 2, 3, 4. This approach has demonstrated reduced exacerbations in asthma when budesonide/formoterol is used as a single inhaler for both daily maintenance and as-needed symptom relief 2, 5. However, MART is not approved or studied for COPD, which is the indication for Trelegy.
Problematic Drug Duplication
A patient on Trelegy is already receiving:
- Fluticasone furoate (inhaled corticosteroid)
- Umeclidinium (long-acting muscarinic antagonist)
- Vilanterol (long-acting beta-agonist)
Adding Symbicort would provide:
- Budesonide (second inhaled corticosteroid)
- Formoterol (second long-acting beta-agonist)
This creates dangerous duplication of both ICS and LABA therapy. Guidelines explicitly warn against using additional LABAs when patients are already on combination therapy 1. The FDA label states: "Instruct patients not to use other LABA for asthma and COPD" 1.
Increased Risk Without Benefit
Doubling up on LABAs increases cardiovascular risks (palpitations, tachycardia, tremor) and corticosteroid-related adverse effects (pneumonia risk, which is already elevated in COPD patients on ICS) 6. The 2015 CHEST/CTS guidelines note a 4% increased pneumonia risk with ICS/LABA combinations 6, and stacking another ICS/LABA on top of triple therapy would compound this risk.
What Should Be Used Instead
For COPD Patients on Trelegy
Use a short-acting beta-agonist (SABA) like albuterol as the rescue inhaler. This is the standard of care and avoids the duplication issues. If rescue medication use increases (>2 days/week), this signals inadequate disease control requiring reassessment of maintenance therapy 1.
Clinical Red Flags
- Increasing SABA use indicates worsening control and potential need for treatment escalation or evaluation for exacerbation triggers
- Decreasing effectiveness of rescue medication requires immediate medical attention 1
- Consider whether the patient is adherent to Trelegy and using proper inhaler technique before adding medications
Common Pitfall to Avoid
Do not confuse the MART strategy used in asthma with general rescue therapy. MART is a specific evidence-based protocol for asthma only where budesonide/formoterol serves dual roles 2, 4. This does not translate to using any ICS/LABA combination as rescue therapy in COPD, especially when the patient is already on triple therapy.
Bottom line: Prescribe albuterol (or another SABA) as the rescue inhaler for this patient, not Symbicort.